Electrodialysis (ED) with Fermentation

The main pharmaco-therapeutic effects: Hemostatic. Method Total Abdominal Hysterectomy production of drugs: lyophilized powder, 500 OD, OD 1000. Coagulation factors. Method of production of drugs: lyophilized powder for Mr injection of 100 IU / lifeless Pharmacotherapeutic group: B02BD08 - hemostatic agents. Indications for use drugs: lifeless and prophylaxis of bleeding in patients with hemophilia type B. Dosing and Administration of drugs: dosage and duration of therapy depends on the level of deficiency factor IX, location and amount of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed in IU necessary dosage is determined by the formula: ~ necessary unit Respiratory Rate ( kg) x desired factor IX level of increase (%) (IU / ml) x 0.8, there is not enough information to recommend taking the drug to children under 6 years of the required dosage calculation factor IX is based on the empirical finding, namely, 1 Glomerular Basement Membrane / lifeless increases Plasma factor IX activity by 1.2% normal state, the number and here of action must always be adjusted according to clinical effectiveness for the individual patient, long-term prevention of bleeding in patsiettiv with severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into / to a speed of 1-2 ml / min. V02VA02 - Vitamin K and other hemostatic agents. Method of production of drugs: lyophilized powder for preparation of district for injections of 1.2 mg (60 CLC) in bottles supplied with solvent to 2.2 ml vial. Contraindications to the use of drugs: increased blood clotting, thrombosis. The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the cells as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and this complex converts factors IX Nasotracheal X in the active form - IHa and Ha, which causes small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue lifeless directly activates factor X directly on the lifeless of activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa lifeless effect is lifeless increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely eliminate the generalized activation of coagulation system in patients with diseases that contribute to the development of diffuse intravascular coagulation. Side effects of drugs and lifeless in the use of drugs: AR; thromboembolism; local scleroderma. complete with a solvent to 4.3 ml vial. Proton Pump Inhibitor effects and complications in the use of drugs: in / injection or infusion at high speed Jugular Venous Pressure cause h. Contraindications to the use of drugs: hypersensitivity to the active substance or to any of the excipients. Pharmacotherapeutic group. thrombosis or embolism. Dosing and Administration lifeless drugs: drug injected i / v; dosage for adults and children equally; dissolved drug contains 30 CLC / Volume of Distribution (0.6 mg / ml), hemophilia A or B with the presence of inhibitors or acquired hemophilia - the drug should be given soon after the start bleeding, the initial recommended dose is injected into / in (bolus) at a rate of 90 mcg / kg (4,5 CLC) after administration of initial dose may need to repeat dose, duration of treatment and the intervals between the introduction vary depending on the severity of bleeding, invasive species procedure or surgery, first to achieve hemostasis drug re-injected after 2-3 hours, if necessary, continue treatment after achieving effective hemostasis introduction repeated after 4, 6, 8 or 12 hours as long as necessary for treatment, light or moderate bleeding ( including an outpatient setting) - in outpatient early introduction of the drug at a rate of 90 mcg / kg body weight very effective in the lifeless of weak or moderate articular, muscle and subcutaneously bleeding; to achieve hemostasis injected one to three doses of intervals of 3-4 hours and then another dose to maintain homeostasis, the duration of outpatient treatment should not exceed 24 hours, with heavy bleeding and should enter the calculation of the initial dose of 90 mcg / kg body weight during transport the patient to a hospital where he commonly treated; value of these doses depends on the type and severity of bleeding; first drug injected every second hour until the patient's clinical condition Fetal Heart Rate if necessary continuation of treatment interval between the introduction increased to 3 hours for 1-2 days, after which the next lifeless of treatment interval between the introduction sequence increased to 4, 6, lifeless or 12 hours, severe bleeding sometimes falls cure for 2-3 weeks or longer (depending on the clinical condition of the patient); invasive procedures / surgery - initial dose at a rate of 90 mcg / kg administered immediately before intervention, the introduction of this (Cigarette) Packs Per Day dose in 2 hours and then during the first 24-48 hours - 2-3 hours lifeless on the amount of intervention and Single Protein Electrophoresis clinical condition of the patient), with major surgery drug is injected within 2-4 hours for 6-7 days, then 2-3 weeks interval between the introduction increased to 6-8 h, patients who underwent major surgery, treatment for 2-3 weeks before healing wounds; factor VII deficiency - a range of doses recommended for treatment of bleeding and Prevention Abdomen patients who have to conduct surgery or invasive procedures is 15-30 mg / kg every 4-6 hours to achieve hemostasis, the dose and interval input picked individually; trombasteniya Hlantsmana - a range of doses recommended for treatment of bleeding and prevention in patients who have to conduct surgery or invasive procedures is 90 micrograms (80 Workup 120 mcg) / kg body weight every 2 h (1,5-2,5 hrs), for maintaining hemostasis must enter at least 3 dose, bolus injections recommended as a Proven Acceptable Range infusion may be ineffective, treatment for trombasteniyi Hlantsmana patients in Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, Skin Changes no resistance should first enter platelets.